



December 8, 2023

To Whom It May Concern

Company: KYORIN Pharmaceutical Co., Ltd.
Representative: Yutaka Ogihara
Representative Director, President and CEO
(Security Code: 4569, TSE Prime.)
Contact: Yoshinori Tanifuji
Director, Corporate Planning
Telephone: 03-3525-4707

Imidafenacin for Overactive Bladder was Launched in Mexico

KYORIN Pharmaceutical Co., Ltd. (hereafter “the Company”) announced today that Imidafenacin was launched in Mexico through Faes Farma, S.A. (Head office: Leioa, Spain, President: Mariano Ucar Angulo, hereafter “Faes”). The Company and Faes executed a collaboration agreement for the exclusive development and distribution rights to Imidafenacin, a treatment for overactive bladder (OAB) that was discovered and developed by the Company, in Latin America (12 central and south countries including Mexico). This is the first market launch in the territory where Faes holds the rights.

Imidafenacin is an anticholinergic agent that acts as a selective antagonist on M3 and M1 muscarinic subtype receptors to improve the urgency of urination, pollakiuria and urge urinary incontinence associated with OAB. In Japan, the Company launched Imidafenacin under the brand name Uritos® 0.1mg tablets in 2007. An additional dosage form of Orally Disintegrating (OD) tablet was launched in 2011.

Through this launch, the Company collaborates with Faes to promote Imidafenacin in Latin America and strive to improve QOL for patients with OAB.

The impact on business performance for the fiscal year ending March 2024 is to be negligible.

Reference

About Faes Farma, S.A.

Established in: 1933

President: Mariano Ucar Angulo

Revenue: EUR 461.7 million (2022)

Employees: 1,766

Overview:

Founded in 1933, Faes Farma is a Spanish pharmaceutical company with an extensive international experience that researches, produces and markets pharmaceutical products and raw materials, exporting to numerous countries. It has more than 1,760 employees and its headquarters, manufacturing and R&D&I center in Leioa (Bizkaia). It has offices in Madrid and Barcelona, and subsidiaries in Portugal, Italy (51% owned), Mexico, Guatemala, Colombia, Chile, Peru, Ecuador, Nigeria and United Arab Emirates. Faes Farma also has a division dedicated to Animal Nutrition and Health (FARM Faes), which includes companies such as Ingaso Farm, Tecnovit, Cidosa and Capselos.

About Overactive Bladder (OAB)

OAB is a urological condition with trouble in pooling urine in the bladder. Its predominant symptoms include urinary urgency and often accompanied by frequent urination and nocturia, in some cases by urge urinary incontinence. All of which lead to significant reduction in patient's quality of life.